Clinical Trial of Alpelisib and Tucatinib in Patients with PIK3CA-Mutant HER2-Positive Metastatic Breast Cancer

被引：0
|
作者：
Shagisultanova, Elena
Wisinski, Kari B.
Gawryletz, Chelsea D.
Datko, Farrah M.
Medgyesy, Diana
Diamond, Jennifer R.
Borges, Virginia F.
Kabos, Peter
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT3-09-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-09-01
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Interim safety analysis of phase IB trial of HER2 inhibitor tucatinib combined with PI3Kα inhibitor alpelisib in HER2+PIK3CA-mutated metastatic breast cancer.
    Gawryletz, Chelsea D.
    Dougherty-Gray, Colleen
    Datko, Farrah Mikhail
    Loch, Michelle Marie
    Sharifi, Marina
    Gopalakrishnan, Ragisha
    Kabos, Peter
    Borges, Virginia F.
    Shagisultanova, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
    Yumi Fujimoto
    Tomoko Yamamori Morita
    Akihiro Ohashi
    Hiroshi Haeno
    Yumi Hakozaki
    Masanori Fujii
    Yukie Kashima
    Susumu S. Kobayashi
    Toru Mukohara
    Scientific Reports, 10
  • [23] " Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper" "
    Conte, Pierfranco
    Ciruelos, Eva
    Curigliano, Giuseppe
    De Laurentiis, Michelino
    Del Mastro, Lucia
    Gennari, Alessandra
    Llombart, Antonio
    Martin, Miguel
    Poggio, Francesca
    Prat, Aleix
    Puglisi, Fabio
    Saura, Cristina
    BREAST, 2024, 76
  • [24] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    Cizkova, M.
    Dujaric, M-E
    Lehmann-Che, J.
    Scott, V.
    Tembo, O.
    Asselain, B.
    Pierga, J-Y
    Marty, M.
    de Cremoux, P.
    Spyratos, F.
    Bieche, I.
    BRITISH JOURNAL OF CANCER, 2013, 108 (09) : 1807 - 1809
  • [25] Patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
    Kaufman, Peter A.
    Neuberger, Edward
    Hsu, Ling-I
    Schwartz, Naomi
    Bartley, Karen
    Wang, Shu
    Liu, Yutong
    Blahna, Matthew T.
    Pittner, Brian T.
    Wong, Gabriel
    Anders, Carey
    CANCER RESEARCH, 2023, 83 (05)
  • [26] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    M Cizkova
    M-E Dujaric
    J Lehmann-Che
    V Scott
    O Tembo
    B Asselain
    J-Y Pierga
    M Marty
    P de Cremoux
    F Spyratos
    I Bieche
    British Journal of Cancer, 2013, 108 : 1807 - 1809
  • [27] Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer
    Shagisultanova, Elena
    Diamond, Jennifer
    Stopeck, Alison
    Pusztai, Lajos
    O'Regan, Ruth
    Gradishar, William
    Brown-Glaberman, Ursa
    Chalasani, Pavani
    McSpadden, Tessa
    Borakove, Michelle
    Shedin, Troy
    Kabos, Peter
    Borges, Virginia
    CANCER RESEARCH, 2018, 78 (04)
  • [28] Targeting PIK3CA in HER2-positive breast cancer: what are the opportunities and the challenges?
    Zouein, Joseph
    Noujaim, Charbel
    Kourie, Hampig Raphael
    BIOMARKERS IN MEDICINE, 2021, 15 (09) : 609 - 613
  • [29] Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer
    Corti, C.
    Criscitiello, C.
    ESMO OPEN, 2021, 6 (02)
  • [30] Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations
    Hyman, David M.
    Tran, Ben
    Paz-Ares, Luis
    Machiels, Jean-Pascal
    Schellens, Jan H.
    Bedard, Philippe L.
    Campone, Mario
    Cassier, Philippe A.
    Sarantopoulos, John
    Vaishampayan, Ulka
    Chugh, Rashmi
    Mahipal, Amit
    Lockhart, A. Craig
    Sessa, Cristiana
    Zander, Thomas
    Ng, Matthew
    Curigliano, Giuseppe
    Bendiske, Jennifer
    Chen, Xueying
    Choudhury, Somesh
    Graus-Porta, Diana
    Lewis, Nancy
    Perez Garcia, Jose Manuel
    Jose de Miguel-Luken, Maria
    JCO PRECISION ONCOLOGY, 2019, 3
12345